Journal
ONCOGENE
Volume 30, Issue 22, Pages 2526-2533Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2010.624
Keywords
p53; ATR; cisplatin; synthetic lethality; gene targeting
Funding
- Flight Attendant Medical Research Institute
- NCI [T32CA121937]
Ask authors/readers for more resources
The protein kinase encoded by the ataxia telangiectasia and Rad3-related (ATR) gene is activated by DNA-damaging agents that are frequently used as anticancer therapeutics. Inhibition of ATR expression in cultured cancer cells has been demonstrated to increase sensitivity to chemotherapeutic drugs, including the DNA-cross-linking agent cisplatin. Cisplatin is a widely used and effective drug, but its use is associated with significant toxicity. Here, we demonstrate that genetic inhibition of ATR expression selectively enhanced cisplatin sensitivity in human colorectal cancer cells with inactivated p53. A knock-in strategy was used to restore wild-type p53 in cells harboring wild-type or mutant ATR alleles. Knock-in of functional p53 in ATR-deficient cells restored checkpoint function, suppressed apoptotic pathways and markedly increased clonogenic survival after cisplatin treatment. These results suggest that a strategy that combines specific inhibitors of ATR and conventional therapies might promote synthetic lethality in p53-deficient tumors, and thus minimize toxicity to normal tissues. Oncogene (2011) 30, 2526-2533; doi:10.1038/onc.2010.624; published online 24 January 2011
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available